C4 Therapeutics (CCCC) Competitors $2.56 +0.05 (+1.99%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$2.60 +0.04 (+1.76%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC vs. DNA, DAWN, PROK, TBPH, IMTX, ABUS, GHRS, KALV, KURA, and SIGAShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Ginkgo Bioworks (DNA), Day One Biopharmaceuticals (DAWN), ProKidney (PROK), Theravance Biopharma (TBPH), Immatics (IMTX), Arbutus Biopharma (ABUS), GH Research (GHRS), KalVista Pharmaceuticals (KALV), Kura Oncology (KURA), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Its Competitors Ginkgo Bioworks Day One Biopharmaceuticals ProKidney Theravance Biopharma Immatics Arbutus Biopharma GH Research KalVista Pharmaceuticals Kura Oncology Siga Technologies C4 Therapeutics (NASDAQ:CCCC) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership. Which has higher valuation & earnings, CCCC or DNA? C4 Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$35.58M5.12-$105.32M-$1.58-1.62Ginkgo Bioworks$227.04M2.96-$547.03M-$5.86-1.93 Which has more volatility and risk, CCCC or DNA? C4 Therapeutics has a beta of 2.98, meaning that its stock price is 198% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Do analysts recommend CCCC or DNA? C4 Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 212.50%. Ginkgo Bioworks has a consensus target price of $9.50, indicating a potential downside of 16.19%. Given C4 Therapeutics' higher possible upside, equities analysts clearly believe C4 Therapeutics is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is CCCC or DNA more profitable? Ginkgo Bioworks has a net margin of -136.56% compared to C4 Therapeutics' net margin of -325.88%. Ginkgo Bioworks' return on equity of -43.25% beat C4 Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-325.88% -53.91% -33.26% Ginkgo Bioworks -136.56%-43.25%-22.29% Do institutionals & insiders hold more shares of CCCC or DNA? 78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by company insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer CCCC or DNA? In the previous week, Ginkgo Bioworks had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Ginkgo Bioworks and 3 mentions for C4 Therapeutics. Ginkgo Bioworks' average media sentiment score of 0.59 beat C4 Therapeutics' score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGinkgo Bioworks beats C4 Therapeutics on 9 of the 16 factors compared between the two stocks. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$185.04M$3.11B$5.77B$9.76BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-1.6221.1082.3426.60Price / Sales5.12357.79502.89158.84Price / CashN/A43.5325.7028.92Price / Book1.048.1310.916.56Net Income-$105.32M-$53.35M$3.28B$266.04M7 Day Performance0.39%0.73%0.09%-0.89%1 Month Performance21.90%7.76%8.93%4.34%1 Year Performance-56.39%11.97%51.81%24.06% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics1.6785 of 5 stars$2.56+2.0%$8.00+212.5%-57.4%$185.04M$35.58M-1.62150News CoverageDNAGinkgo Bioworks1.0405 of 5 stars$12.06-3.9%$9.50-21.2%+86.0%$742.96M$227.04M-2.06640Gap UpDAWNDay One Biopharmaceuticals2.3151 of 5 stars$6.97-3.2%$25.29+262.8%-44.6%$737.51M$131.16M-7.3460Positive NewsPROKProKidney3.3572 of 5 stars$2.35-2.5%$6.25+166.0%-1.7%$709.22M$80K-4.123News CoverageTBPHTheravance Biopharma3.6297 of 5 stars$13.80-0.8%$21.33+54.6%+71.6%$700.53M$64.38M57.50110Positive NewsIMTXImmatics2.2 of 5 stars$5.23-8.1%$14.67+180.4%-50.7%$691.62M$168.65M-8.05260ABUSArbutus Biopharma2.5767 of 5 stars$3.50-2.5%$5.50+57.1%-1.5%$688.20M$6.17M-12.0790News CoveragePositive NewsGHRSGH Research1.711 of 5 stars$13.18+0.8%$32.00+142.8%+42.9%$680.53MN/A-17.8110News CoverageKALVKalVista Pharmaceuticals4.0436 of 5 stars$12.99-3.1%$26.29+102.4%+14.5%$675.06MN/A-3.52100News CoveragePositive NewsKURAKura Oncology3.8295 of 5 stars$7.65flat$24.10+215.0%-58.3%$664M$53.88M-3.38130News CoveragePositive NewsSIGASiga Technologies2.3816 of 5 stars$8.70-4.7%N/A+11.5%$653.76M$138.72M7.7040News CoverageOptions Volume Related Companies and Tools Related Companies Ginkgo Bioworks Competitors Day One Biopharmaceuticals Competitors ProKidney Competitors Theravance Biopharma Competitors Immatics Competitors Arbutus Biopharma Competitors GH Research Competitors KalVista Pharmaceuticals Competitors Kura Oncology Competitors Siga Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CCCC) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
